December 15, 2021
More bad news for Medtronic, more good news for Lilly
Not like they needed more bad news Medtronic diabetes got some when they received an FDA warning letter. According to a press release issued this morning-
“The warning letter focuses on the inadequacy of specific medical device quality system requirements at the Northridge facility in the areas of risk assessment, corrective and preventive action, complaint handling, device recalls, and reporting of adverse events.”
It goes without saying that this is just one more reason why the company should stop screwing around and exit diabetes entirely. Once the undisputed leader in the insulin pump market the company is not . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
